Chelsea Therapeutics (CHTP) Reports Better-Than-Expected Q3 Loss of $0.22
CHTP Hot Sheet
EPS Growth %: +20.0%Financial Fact:
Operating loss: -15.59M
Today's EPS Names:
TARO, BRLI, TLB, More
Chelsea Therapeutics (NASDAQ: CHTP) reports Q3 loss of $0.22, 6 cents better than the analyst estimate of ($0.28).
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Tiffany & Co. (TIF) Misses Q1 EPS Views; Lowers FY12 EPS, Revs Growth Outlook
- Patterson Companies, Inc. (PDCO) Tops Q4 EPS by 5c; Guides FY12
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
